vx-135
Small moleculeexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2012 (NCT01726946)
Timeline
2010s
- Jan 1, 2012
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Genome polyproteinINHIBITOR
Genome polyprotein inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CC(C)OC(=O)[C@H](C)NP(=S)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(O)[C@@H]1O)Oc1ccccc1- Mol. weight
- 543.54 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4783446 ↗
Also known as
- vx-135
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01842451 | Phase 2 | Jun 1, 2013 | Vertex |
| NCT01790100 | Phase 2 | Feb 1, 2013 | Alios BioPharma, Vertex |
| NCT01726946 | Phase 2 | Nov 1, 2012 | Vertex |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Vertex | For profit | 3 | 2 | 1 | 2012 |
| Alios BioPharma | For profit | 1 | 1 | 1 | 2013 |
2 organizations
Page 1 / 1